Emcure Pharmaceuticals touches the roof on getting nod to incorporate wholly-owned subsidiary
Emcure Pharmaceuticals is locked its upper circuit at Rs. 1288.65, up by 117.15 points or 10.00% from its previous closing of Rs. 1171.50 on the BSE.
The scrip opened at Rs. 1202.10 and has touched a high and low of Rs. 1288.65 and Rs. 1202.10 respectively. So far 22398 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1577.50 on 18-Sep-2024 and a 52 week low of Rs. 890.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1288.65 and Rs. 1046.80 respectively. The current market cap of the company is Rs. 24417.77 crore.
The promoters holding in the company stood at 77.92%, while Institutions and Non-Institutions held 6.51% and 15.57% respectively.
Emcure Pharmaceuticals has received approval for incorporation of a wholly-owned subsidiary (WOS) by the name ‘Emcure Generics’ in Pune, Maharashtra, India. The WOS is being incorporated to manufacture, promote, sale and distribute pharmaceuticals and other related product(s).
The Board of Directors of the company in their meeting held May 22, 2025, has approved the same.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
